Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Seeing Is Believing—Plaque Growth Is Slow, Tapers With Age
17 January 2011. To understand how amyloid plaques, the troublesome clumps of Aβ, form and grow in the brain, it helps to just watch the action directly. Advances in multiphoton microscopy have made this possible, allowing scientists to see individual plaques develop within the brains of living mice in real time. Researchers in Germany have now refined the technique to track plaque formation and growth in AD mouse models for up to six months—the longest ever recorded. Two new studies show that plaques grow slowly over time and reach a plateau in older, amyloid-laden animals. The new insight into plaque formation dynamics could enable better monitoring of amyloid-lowering compounds in preclinical development.

The first study, led by Mathias Jucker at the University of Tübingen, Germany, appears in this week’s Journal of Neuroscience. The second study, by Jochen Herms, Ludwig-Maximilians University, Munich, and colleagues was posted December 6 online in Acta Neuropathologica.

A few specialized labs have used in vivo multiphoton microscopy to peer into the brains of AD transgenic mice and track plaque growth through tiny cranial windows. Because it is done in live animals, the analysis is painstaking. Scientists typically rely on fluorescent cells and blood vessels as landmarks to realign the field of view for repeated imaging across multiple time points. However, “because the picture is three-dimensional, if your angle is slightly off, your perspective on the plaque changes,” said Jin-Moo Lee of Washington University School of Medicine in St. Louis, Missouri, who has used two-photon imaging to study plaque dynamics in AD mice, but was not involved in the recent studies.

In Jucker’s paper, first authors Jasmin Hefendehl and Bettina Wegenast-Braun, and colleagues describe a new head restraint system that allows more efficient and accurate multiphoton analysis. The researchers drill a 4-mm-wide hole into the mouse’s skull, seal it with a coverslip, and cement onto that a custom-built titanium ring that fits precisely into a small notch on a motorized stage. Instead of using cells and vessels as signposts to find previously imaged brain areas, “you can basically press a button that does that automatically,” Hefendehl told ARF.

Between imaging sessions, the mice scamper freely, and their behavior and lifespan appear unaffected by the titanium structure fixed to their heads. “We have some mice that have lived quite happily with the ring for two years,” Hefendehl said. Mice can be fitted with the rings once their bone structure is calcified—as early as three months of age—she noted.

Using the new method, which will be described in an upcoming issue of Nature Protocols, the researchers watched plaques develop in the brains of APP/PS1 mice starting at three to four months of age, when amyloid pathology is rampant in this strain. Jucker and colleagues imaged over a 25-week period—a record thus far for multiphoton microscopy studies of AD mice. Imaging weekly for the first two months, biweekly for the next month, and monthly up to 25 weeks, the scientists studied nearly 400 plaques in seven mice, each mouse analyzed at six locations. They observed a period where new plaques form rapidly and grow steadily, and a later phase where the number of new plaques forming peters off.

To analyze the dynamics of this process, the scientists first measured the size distribution of plaques in mice of increasing age (four, seven, and nine months). Four-month-old animals had mostly small plaques of less than 16 micrometers across, whereas plaque size shifted toward larger (up to 44 micrometers diameter) in older mice. Consistent with their predominance in younger animals with less advanced disease, new plaques were small—only 13 percent had a diameter over 8 micrometers, whereas more than three quarters of pre-existing plaques were larger than that.

The team also analyzed changes in volume and diameter for new and already formed plaques. In the volume analysis, new plaques showed higher-fold increases over time, whereas existing plaques showed very little change when assessed in this way. However, when growth was measured in terms of diameter, both types of plaque grew at similar rates. This makes mathematical sense, since a linear increase in diameter would mean that small plaques grow more robustly than large ones when comparing fold increases in volume. “The underlying physiological model suggests that new amyloid ‘layers’ are constantly added to the surface of existing plaques—despite the difference in initial size,” the authors write.

Bulking Up
Long-term multiphoton imaging shows growth of amyloid plaques (green) in the brains of APP/PS1 transgenic mice starting at 3.7 months of age. Blood vessels are stained red. View larger image. Image credit: Hefendehl et al. The Journal of Neuroscience 2011

In the Acta Neuropathologica paper, first author Steffen Burgold and colleagues used a similar approach to visualize plaques in AD mice. The researchers made a small incision in the skull, glued on a coverslip, then attached a small metal bar containing a hole for a screw, to enable repositioning of the mouse for repeated imaging sessions. Compared to Jucker’s team, they analyzed plaque formation over a shorter period (six weeks), and used an AD strain (Tg2576) with slower amyloidosis. Tg2576 mice start accumulating brain amyloid around nine to 10 months.

In weekly imaging sessions, the researchers studied 83 plaques in 12-month-old Tg2576 mice, and found that newborn plaques were, on average, considerably smaller in volume than pre-existing ones, suggesting that plaques take on the order of weeks to mature. Both types grew steadily over time, though relative volumes increased more quickly for newborn than for pre-existing plaques. These patterns corroborate Jucker’s findings in APP/PS1 mice with amyloid pathology well underway. However, older (18-month-old) Tg2576 mice did not form new plaques, and their pre-existing ones hardly increased in volume, over the six-week imaging period.

Overall, the two studies found that new plaques start off small and steadily bulk up before reaching a maximum girth in older mice with more advanced disease. The observation that plaques stop growing in old mice is not new (see Christie et al., 2001). Why that happens remains speculative. In aging mice with “lots of plaques around, soluble Aβ peptides have many choices as to where they can go, making it harder for the growth of any single plaque to be detected,” Herms suggested. As for the age-related decline in the rate of new plaque formation, Hefendehl proposed that it may be a passive process where “existing plaques take up amyloid-β that is floating around. “If there are no plaques to take up the soluble Aβ, then there could be a critical concentration of Aβ present to seed a new plaque,” she said.

The current data contrast with the results of a multiphoton microscopy study by Brad Hyman and colleagues at Massachusetts General Hospital in Boston. Imaging plaques in three AD strains, including the Tg2576 mice, the scientists found a significant number of plaques that sprang up overnight with no further growth in the subsequent two-week imaging (Meyer-Luehmann et al., 2008 and ARF related news story). “Some plaques were very big. To think they just appeared in 24 hours was quite amazing,” said Herms said of that study.

Lee and colleagues did their own multiphoton analysis that offered a reason for the apparent lack of plaque growth in the Hyman study. The researchers imaged β amyloid in APP/PS1 transgenic mice and found plaques growing steadily over a period of weeks, not days (Yan et al., 2009 and ARF related news story). However, plaque growth was observed only when the scientists used an alternative method that involved paring the skull to near transparency and imaging through those ultra-thin bone windows. When they drilled all the way through to create open-skull windows, like those used in the Jucker and Herms studies, the WashU team saw considerable gliosis, which they believe stunted further growth of plaques that formed at early timepoints. A recent Nature Methods paper describes a new approach that improves the durability of thin-skull windows, and discusses the ongoing controversy around procedure-induced gliosis (Drew et al., 2010).

In their recent study, Herms and colleagues averted potential inflammatory responses associated with the open-skull procedure by waiting three weeks after surgery to begin imaging. Jucker’s group delayed imaging for just one week, but detected no gliosis—or in this case, proliferation of microglia expressing green fluorescent protein. Staining mouse brains for activated microglia (Iba-1) and astrocytes (GFAP) a week after the open-skull procedure also found no differences between surgically treated mice and control animals. In addition, the Jucker lab optimized the surgery so the skull can be lifted carefully without disrupting the dura matter. “By now, up to 90 percent of the craniotomies we do produce no gliosis,” noted Wegenast-Braun.

Regardless of procedural differences, scientists cite imaging duration as the prime reason for the apparent discrepancy between the plaque growth dynamics seen in Hyman’s study versus other reports. In an e-mail to ARF, Jucker noted that he thinks his new data “do not nullify” Hyman’s findings. “It just extends his work by showing that amyloid plaques grow over time if imaging is done over a long period,” Jucker wrote. Melanie Meyer-Luehmann, first author on the Hyman paper, agrees, noting that the two present studies “show very nicely that plaques can indeed appear very quickly and therefore confirm what we previously published in three different APP transgenic lines.” Before joining the Hyman lab as a postdoc, Meyer-Luehmann did her Ph.D. studies under Jucker, and now heads her own research group at Ludwig-Maximilians University in Munich.

Taken together, the current work strengthens an emerging consensus in multiphoton imaging studies—plaques can initially appear quickly, then grow slowly over long periods and taper in aging animals with extensive amyloid pathology. “There are now three independent groups that have confirmed this using different techniques and different animal models,” Lee noted. By helping to flesh out the growth dynamics of new and existing Aβ plaques, the data may improve future preclinical testing of potential amyloid-lowering agents for AD and other diseases.—Esther Landhuis.

References:
Hefendehl JK, Wegenast-Braun BM, Liebig C, Eicke D, Milford D, Calhoun ME, Kohsaka S, Eichner M, Jucker M. Long-term in vivo imaging of beta-amyloid plaque appearance and growth in a mouse model of cerebral beta-amyloidosis. J. Neurosci. 2011;31(2):624-629. Abstract

Burgold S, Bittner T, Dorostkar MM, Kieser D, Fuhrmann M, Mitteregger G, Kretzschmar H, Schmidt B, Herms J. In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks. Acta Neuropathol. 2010 Dec 6. Abstract

 
Comments on News and Primary Papers
  Primary Papers: Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice.

Comment by:  Gunnar K. Gouras
Submitted 2 September 2009  |  Permalink Posted 2 September 2009

This is an excellent study by Lee and colleagues employing serial multiphoton microscopy (MPM) to provide more clues to the process of plaque formation in the living brain of a well-established APP/PS1 transgenic mouse model of Alzheimer disease. Previous work by Hyman and colleagues had provided novel observations on the remarkably rapid appearance of plaques, and had also noted that once formed, there was little additional growth in the size of plaques. The focus of the current study is less the appearance and more the growth in the size of existing plaques over a time frame of a few weeks using a thinned skull window approach. They provide intriguing evidence for the importance of the type of window used to visualize plaques. Specifically, Lee and colleagues show that the open craniotomy with coverslip approach used in previous MPM studies in AD prevents the further growth of plaques and even augments regression of some plaques when compared with the thin-skull method. With the open- but not thin-skull method, there is marked cortical activation of inflammatory cells below the...  Read more

  Primary Papers: Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice.

Comment by:  Samir Kumar-Singh
Submitted 2 September 2009  |  Permalink Posted 2 September 2009

Yan and colleagues add another piece to the plaque kinetics puzzle by showing, with on multiphoton in vivo microscopy, that amyloid plaques in a bigenic PSAPP mouse model appear and grow over a period of weeks before reaching a mature size. These data seem to be in apparent conflict with earlier work using the same technique on related mouse models (Meyer-Luehmann et al. 2008), where dense plaques were shown to reach their maximum size in about a day and thereafter maintain a status quo.

The present study also goes forward to propose a reason for this discrepancy. Amyloid imaging through large open-skull cranial windows (as utilized solely by Meyer-Luehmann and colleagues) seems to activate gliosis, in contrast to thinned-skull windows of ≈1/10th the size, where calvaria are merely thinned down to allow in vivo microscopy without exposing the dura mater. This seems logical, as activation of gliosis has been shown in several studies to be an important factor in limiting plaque growth (  Read more


  Primary Papers: Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice.

Comment by:  Bart De Strooper, ARF Advisor
Submitted 2 September 2009  |  Permalink Posted 2 September 2009

This is excellent work. The authors make elegantly the case that the procedures used to visualize amyloid plaques in vivo may strongly affect the generation and dynamics of the plaques. It is also of strong interest that interstitial Aβ peptide is such an important contributor to the plaque dynamics, as this is a rather small pool of total Aβ in the brain, and also highly dynamic and influenced by medication. Finally, the fact that 20-30 percent changes in that pool strongly affect the plaque formation should indeed raise hope that a therapeutic window exists for secretase inhibitors.

I strongly recommend the paper.

View all comments by Bart De Strooper


  Primary Papers: Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice.

Comment by:  Melanie Meyer-Luehmann
Submitted 24 September 2009  |  Permalink Posted 24 September 2009

In my opinion, the discussion above misses one important fact: Brad Hyman's group published already in 2001 that plaques do not grow over time and that there is a restriction on plaque growth (Christie et al., 2001). In that study, more than 300 plaques were analyzed with two-photon microscopy over a time period of up to five months, and the investigators found the majority of plaques remained unchanged in size over time. Even more importantly, the data were observed using the thinned-skull method, i.e., the same method used by Yan et al., 2009. Therefore, thinned-skull versus open-skull preparation alone cannot account for the opposing result.

View all comments by Melanie Meyer-Luehmann

  Primary Papers: Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice.

Comment by:  Jin-Moo Lee
Submitted 26 September 2009  |  Permalink Posted 28 September 2009

We appreciate the comments of Dr. Meyer-Luehmann. However, the absence of plaque growth reported in the Christie et al. (2001) paper is very consistent with the data reported in our recent paper (Yan et al, 2009). Although we observed marked plaque growth in six-month-old APP/PS1 mice (early in plaque pathogenesis), we saw little to no growth in 10-month-old APP/PS1 mice. Of note, the Christie et al. paper did not see plaque growth in 18-month-old (mean age) Tg2576 mice. Therefore, our observations in older animals who have more advanced pathology are in agreement with the Christie et al. paper.

References:
Christie RH, Bacskai BJ, Zipfel WR, Williams RM, Kajdasz ST, Webb WW, Hyman BT. Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J Neurosci. 2001 Feb 1;21(3):858-64. Abstract

View all comments by Jin-Moo Lee

  Primary Papers: Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice.

Comment by:  Chris Exley
Submitted 6 October 2009  |  Permalink Posted 6 October 2009

This and other research demonstrates the deposition of Aβ in vivo in an animal model. Do we know that the “structures” that are shown being formed are also the same structures that are identified histo- or immunochemically postmortem?

Thus, are we confident that what is observed is the full process that results in the structures that we identify classically as plaques postmortem?

The alternative is that we are observing one part of a process. In some instances what is deposited may eventually be removed or transformed to something else and it is this “something else” which we identify postmortem as senile plaques.

Are senile (neuritic) plaques simply deposits of Aβ, or are they more than this?

View all comments by Chris Exley


  Comment by:  Jason Frommer
Submitted 26 January 2011  |  Permalink Posted 26 January 2011
  I recommend the Primary Papers

As a graduate student who reviewed this subject in great detail for a journal club (see Meyer-Luehmann et al., 2008 and Yan et al., 2009), I am surprised at some of the opinions presented here after these most recent papers on plaque dynamics (Hefendehl et al., 2011; Burgold et al., 2010), which I think are interesting and thorough examinations of plaque growth in vivo. In contrast, when reviewing the initial paper on this topic from the Hyman Lab (Meyer-Luehmann et al., 2008), it became apparent to me and the people with whom I discussed it that the reason why they saw very rapid plaque appearance and no further plaque growth within 14 days was because of an artifact of incomplete dye labeling. If one inspects in detail Figure 1 in their paper, one can see that the plaque that “appeared” after 24 hours of dye injection was really present even before...  Read more

  Comment by:  Brian Bacskai, ARF Advisor, Bradley Hyman, ARF Advisor
Submitted 6 February 2011  |  Permalink Posted 6 February 2011

Several papers now have used multiphoton imaging to monitor plaques over time in AD transgenic models (Hefendehl et al., 2011; Burgold et al., 2010; Yan et al., 2009), following on the initial work we published in 2001 (Christie et al., 2001). Over the years we have imaged thousands of plaques using either “thin skull” or “coverslip” approaches in three different APP or APP/PS1 overexpressing models. The new papers, emerging from analogous work at Washington University and in Germany, show similar approaches to dissect the natural history of plaques in living animals.

Overall, there is general concurrence in our observations. It is obvious that animals initially have no plaques, then many months later have many plaques. What happens in between? We found that plaques form surprisingly quickly, then reach a near maximal size within days. The other groups, using slightly different models and...  Read more

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad